Cochrane Review Group
Schizophrenia
168 systematic reviews in Schizophrenia ask 2,589 questions. 23.2% have no studies to answer them, 27.8% rest on very low certainty evidence and 12.2% reach moderate or high certainty.
Reviews
168
Questions
2,589
current versions
No studies
23.2%
Moderate or high
12.2%
No studies 601 · 23.2%Ungraded 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Collaborative care vs usual care Quality of life: average change in mental health component (proxy for binary quality of life) · severe mental illness Collaborative care approaches for people with severe mental illness (2024) · Cochrane | no estimate extracted | 3 studies · 227 participants | Very low |
Summary of findings table ‐ Collaborative care vs usual care Quality of life: average change in physical health component (proxy for physical health) · severe mental illness Collaborative care approaches for people with severe mental illness (2024) · Cochrane | no estimate extracted | 3 studies · 237 participants | Very low |
Summary of findings table ‐ Collaborative care vs usual care Personal recovery ‐ not reported · severe mental illness Collaborative care approaches for people with severe mental illness (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Collaborative care vs usual care Experience of care/satisfaction ‐ not reported · severe mental illness Collaborative care approaches for people with severe mental illness (2024) · Cochrane | no estimate extracted | NR | No studies |
Structured risk assessment vs standard professional care Adverse effects (escape) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 0.2 [0.01, 4.11] | 1 study · 200 participants | Very low |
Structured risk assessment vs standard professional care Adverse effects (fall down) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 0.33 [0.04, 3.15] | 1 study · 200 participants | Very low |
Structured risk assessment vs standard professional care Adverse effects (choking) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 0.2 [0.01, 4.11] | 1 study · 200 participants | Very low |
Summary of findings table ‐ Cognitive behavioural therapy plus standard care vs control Adverse events ‐ participants with at least one adverse event ‐ < 12 months · first‐episode or recent‐onset psychosis Cognitive behavioural therapy added to standard care for first‐episode and recent‐onset psychosis (2024) · Cochrane | RR 1.29 [0.85, 1.97] | 1 study · 43 participants | Very low |
Summary of findings table ‐ CBT without antipsychotics vs antipsychotics Adverse events ‐ Participants with at least one AE (separated time points) ‐ < 12 months · schizophrenia Cognitive behavioural therapy without medication for schizophrenia (2024) · Cochrane | RR 0.47 [0.21, 1.07] | 1 study · 40 participants | Very low |
Summary of findings table ‐ CBT without antipsychotics vs CBT plus antipsychotics Mental state ‐ general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points) ‐ < 12 months · schizophrenia Cognitive behavioural therapy without medication for schizophrenia (2024) · Cochrane | no estimate extracted | 3 studies · 125 participants | Very low |
Summary of findings table ‐ CBT without antipsychotics vs CBT plus antipsychotics Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ < 12 months · schizophrenia Cognitive behavioural therapy without medication for schizophrenia (2024) · Cochrane | RR 2.89 [0.12, 67.75] | 1 study · 90 participants | Very low |
Summary of findings table ‐ CBT without antipsychotics vs CBT plus antipsychotics Leaving the study early ‐ for any reason ‐ overall acceptability (separated time points) ‐ < 12 months · schizophrenia Cognitive behavioural therapy without medication for schizophrenia (2024) · Cochrane | RR 0.7 [0.12, 4.11] | 2 studies · 90 participants | Very low |
Reviews 168
Information and communication technology based prompting for treatment compliance for people with serious mental illness
CochraneSoF table
7 questions
Trifluoperazine versus placebo for schizophrenia
CochraneSoF table
7 questions
User‐held personalised information for routine care of people with severe mental illness
CochraneSoF table
6 questions
Pimozide for schizophrenia or related psychoses
CochraneSoF table
32 questions
Haloperidol dose for the acute phase of schizophrenia
CochraneSoF table
7 questions
Haloperidol versus placebo for schizophrenia
CochraneSoF table
7 questions
Training to recognise the early signs of recurrence in schizophrenia
CochraneSoF table
7 questions
Intermittent drug techniques for schizophrenia
CochraneSoF table
42 questions
Quetiapine versus other atypical antipsychotics for schizophrenia
CochraneSoF table
42 questions
Dance therapy for schizophrenia
CochraneSoF table
7 questions
Quetiapine versus typical antipsychotic medications for schizophrenia
CochraneSoF table
7 questions
Supported employment for adults with severe mental illness
CochraneSoF table
6 questions
Atypical antipsychotics for psychosis in adolescents
CochraneSoF table
19 questions
Nidotherapy for people with schizophrenia
CochraneSoF table
7 questions
Preventive interventions for postnatal psychosis
CochraneSoF table
5 questions
Life skills programmes for chronic mental illnesses
CochraneSoF table
10 questions
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses
CochraneSoF table
11 questions
Bromperidol decanoate (depot) for schizophrenia
CochraneSoF table
13 questions
Management of sexual dysfunction due to antipsychotic drug therapy
CochraneSoF table
27 questions
Benzodiazepines for schizophrenia
CochraneSoF table
17 questions
Information and communication technology in patient education and support for people with schizophrenia
CochraneSoF table
14 questions
Acetylcholinesterase inhibitors for schizophrenia
CochraneSoF table
7 questions
Paliperidone palmitate for schizophrenia
CochraneSoF table
14 questions
Flupenthixol versus placebo for schizophrenia
CochraneSoF table
7 questions
Psychoeducation for schizophrenia
CochraneSoF table
7 questions